In a report released today, Emily Bodnar from H.C. Wainwright initiated coverage with a Buy rating on MiNK Therapeutics (INKT – Research Report) and a price target of $10.00. The company’s shares closed yesterday at $1.62.
Bodnar covers the Healthcare sector, focusing on stocks such as Dice Therapeutics, Agenus, and Context Therapeutics. According to TipRanks, Bodnar has an average return of -8.6% and a 37.36% success rate on recommended stocks.
MiNK Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.00.
See today’s best-performing stocks on TipRanks >>
INKT market cap is currently $54.94M and has a P/E ratio of -2.11.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
Read More on INKT:
- MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
- MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
- MiNK Therapeutics announces clinical data of allogeneic iNKT cells
- MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
- MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI
